Next Stage Solutions Announces Three New Financial Services For Emerging Business
Solutions, Inc. has expanded its financial services offerings to further meet the needs of emerging businesses. Specifically, Next Stage
Solutions (NSS) has launched three new services: First, CFO on Demand - NSS partners with their clients acting as an outsourced CFO on an as-needed ...
Index Ventures Closes Euro 350 Million Early Stage Fund
Ben Holmes Named Partner
LONDON, March 3 /PRNewswire/ -- Index Ventures today announced the closing of a euro 350 million early stage
fund, Index Ventures V. The fund is dedicated to early stage
and seed investments in the technology, biotechnology and clean technology sectors across Europ...
News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009
Industry leaders, experts and foreign ministry delegations set to be involved in Asia Pacific's largest homeland security Conference and Exhibition.
Singapore (PRWEB) March 2, 2009 -- Asia-Pacific's largest and most comprehensive homeland security and counter terrorism ...
Implicit Licenses Clinical Stage Antibody Program From Lilly
BRISBANE, Australia and SEATTLE, Feb. 24 /PRNewswire/ -- Implicit
Bioscience Ltd today announced the acquisition of the clinical-stage
monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an
undisclosed consideration combining cash and stock to Lilly. Lilly will also
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles-
TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that its lead product candidate bavituximab achieved th...
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
(NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on
endocrine therapy and oncology, today reported that it has entered the
of patient recruitment for its Phase 2 trial in endometrial
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in
of Trial Assessing Regimen of Bavituximab with Carboplatin and Paclitaxel -
TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ...
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
KENILWORTH, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug
Administration (FDA) has accepted the Peg-IFN (peginterferon alfa-2b)
supplemental Biologics License Application (sBLA) for review and has
granted Priority ...
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Oral Presentation of the US Oncology Adjuvant Trial 9735 at 2007 San
Antonio Breast Cancer Symposium Showed Taxotere(R) and Cyclophosphamide Improved Overall Survival Versus An Anthracycline Combination
SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Results presented at the
National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
This development places National Stem Cell in the sector for Anti-aging
products and services, presently a $30 Billion Market, and one of the Biggest Marketing Opportunities in the U.S. Today
MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem
Cell Holding, Inc. (O...
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
-- Further analysis of phase 2 breast cancer data show preferential
activity of adecatumumab on inhibiting the formation of new metastases
-- Results from 169 patients treated with adecatumumab demonstrate an apparent lack of immunogenicity of the antibody
BETHESDA, Md., Oct...
OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye
MIAMI, Oct. 10 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK )
today announced that it has acquired exclusive worldwide rights for
ophthalmic uses to a topical clinical stage
compound with potential utility
in the treatment of dry eye. "Dry eye is an increasingly common condition tha...
HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
SAN DIEGO and SHANGHAI, China, Oct. 2 /PRNewswire/ -- HUYA Bioscience
International (HUYA), a rapidly expanding biopharmaceutical company focused
on the development of key disease-fighting drugs sourced from China,
announced today that it has licensed a novel clinical stage
Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
BEIJING and CLAREMONT, Calif., Sept. 26 /Xinhua-PRNewswire-FirstCall/
-- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
today announced that its wholly owned subsidiary, Kiwa Bio-Tech Products
(Shandong) Co., Ltd., has completed the first stage
of the planned
upgrading of ...
Neah Power Systems A seed stage venture capital model
Developing a viable technology company requires insight, discipline, and a relentless focus on developing technology, business and marketing plans. Many successful startups create a high-value company by defining a big problem with a large focused market opportunity for the development of new produ...
An analysis of Wisconsins new venture capital and early stage finance programs
If high tech is the engine of future economic growth, Wisconsin is running low on investment fuel. A recent study by the California-based Milken Institute ranks our state 32nd out of 50 in availability of the risk capital that technology entrepreneurs need to turn innovative ideas into marketplace...
With Sarbanes-Oxley, compliance takes center stage for CIOs
If, five years ago, you asked a group of chief information officers for their number-one issue, they might have said storage capacity, security or bandwidth.
Today, the consensus issue is compliance, particularly with the new spate of securities legislation, highlighted by Congress's passage of ...
Early Stage Symposium session will help emerging companies prepare for investors
Madison, Wis. - Companies that register for the Oct. 19-20 Wisconsin Early Stage
Symposium may attend a seminar that will help them prepare to seek private equity at the state, regional and even national level.
"Venture Readiness Tools for Commercialization Success" will be held Oct. 20 as a ...
Early Stage Step 2: Choosing a domain name
Editor's note: This is the second in a series of articles on developing start-up companies in the technology or biotechnology realm. The first edition of Early Stage
focused on protecting your intellectual property.
Madison, Wis. - So now that you know you have a patentable technology or...
Early Stage 7, Part I: Just what is an employee?
Editor's note: This is the seventh in a series of articles on developing start-up companies in the technology or biotechnology sectors. The most recent article focused on business taxes.
Madison, Wis. - Your entity is formed and you are ready to begin hiring workers. As discussed in the pr...
Early Stage 10: The nuances of federal laws
Editor's note: This is the 10th in a series of articles on developing start-up companies in the technology or biotechnology sectors.
Madison, Wis. - In Step 9 we discussed general concepts on the securities laws. This time we focus specifically on the federal laws.
Any business that of...
Internet-enabled niche markets take center stage
Madison, Wis. - Whether you pronounce it nitch or the more cosmopolitan neesh, the term niche is spelled the same way, and thanks in large measure to the Internet, it increasingly spells growth and profit.
An entire conference, Brandworks University 2007 , is centered on what some are calling...
...or on a paper that reported these results in the journal Science. "In our study, we found that coalescence events are frequently involved in the early stage
of nanocrystal growth and yet
monodisperse nanocrystals are still formed."
Says Alivisatos, a chemist who holds joint appointments with Berkeley La...
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
...ties up to an aggregate public offering price of $40 million. However, the financial markets have been very difficult for companies at our development stage
and financial condition and financing may not be available on favorable terms or at all. Additionally, we have received notice from the NYSE Amex that...
Novavax Reports Second Quarter 2009 Financial Results
..., other non-dilutive financing, or additional partnering agreements, as opportunities arise.
Novavax, Inc. is a clinical stage
biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particl...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
...nd $112,524, respectively.
As a development stage
biopharmaceutical company, Catalyst has no revenue..., INC.
(a development stage
CONDENSED STATEMENTS O..., INC.
(a development stage
NeurogesX Reports Second Quarter 2009 Results
...painful diabetic neuropathy (PDN). NeurogesX' late stage
product portfolio is led by its product candidate ...rther development efforts.
NeurogesX' early stage
product pipeline includes pre-clinical compounds, ...X, INC.
(A Development stage
Telik Announces Second Quarter 2009 Financial Results
...luding restricted investments, compared to $63.5 million at December 31, 2008.
Telik, Inc. of Palo Alto, CA, is a clinical stage
drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most adv...
PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
...he field of Alzheimer's drug development," says Dr. Fillit.
"At ADDF, we are about results - bridging the gap between basic research and later stage
drug development in humans. Alzheimer's is the fifth leading cause of death in the elderly and the third most costly disease overall. We're seeking to...
The Breast Cancer Therapeutics Market in Australia
... detection of breast cancer, have resulted in oncologists seeing more early stage
disease. This, combined with aggressive and targeted therapy has, in turn, ...ts Scheme (PBS)," says Gaffud.
Currently, only Herceptin (for early stage
breast cancer patients) and Tykerb (for advanced/metastatic breast cancer p...
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
...neuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage
product portfolio is led by its product candidate Qutenza(TM), a dermal pat...e design and timing of further development efforts.
NeurogesX' early stage
product pipeline includes pre-clinical compounds, which are prodrugs of ace...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...le-blind, randomized, placebo-controlled treatment stage
and will enroll approximately 60 subjects who are ...t all stages of a company's development, from seed stage
through IPO. With approximately $8.5 billion in co...ics, Inc.
(a development stage
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
... CADENCE PHARMACEUTICALS, INC.
(a development stage
CONDENSED STATEMENTS OF OPERATIONS
... CADENCE PHARMACEUTICALS, INC.
(a development stage
CONDENSED BALANCE SHEETS
Pharmasset to Present at Canaccord Adams Conference
...ys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage
candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the trea...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... the 2009 ASCO annual meeting. Results demonstrated that the Onco type DX colon cancer test can independently predict individual recurrence risk for stage
II colon cancer patients following surgery. Importantly, the Onco type DX colon cancer Recurrence Score(R) provided additional independent clinical v...
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
...nder of ELARA
Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia
Signaling inhibitor program to move from academic discovery stage
proof of concept. This led to a successful spin off from the European
Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
...velopment of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes repurposed clinical stage
therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eig...
OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
...cal trials. Phase I clinical trials are the first stage
of the US or International regulatory approval pro...ster(R) software, which is primarily used in later stage
clinical trials. The Logos products cover all aspe...sample management. Regular EDC solutions for later stage
trials do not include a pro-active data collection...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
... a 90 percent premium. With the acquisition Bristol-Myers Squibb gains full rights to ipilimumab, an experimental drug for metastatic melanoma in late stage
testing. The companies together have been developing the drug, which is also being studied in lung and prostate cancers. Bristol also gains rights to ...
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
...ars as part of the Phase 2b trial in patients with stage
IIIb/IV non-small cell lung cancer (NSCLC).
As o...se progression. Nine of the 10 living patients had stage
IIIb NSCLC upon entry to the trial, while one had stage
IV disease. Six of the 10 living patients had a co...